Stock Movers Merck to Buy Terns Pharmaceuticals; Arm to Sell Its Own Chips; Braze Shares Climb
Mar 25, 2026
A corporate takeover makes waves with a big biotech buyout. A chip-IP giant pivots to selling its own processors and aims for huge data-center revenue. A software company beats sales expectations and rolls out AI-driven products. Industrywide chip shortages and price hikes loom over the tech sector.
AI Snips
Chapters
Transcript
Episode notes
Merck Acquires Terns For Targeted Blood Cancer Play
- Merck will buy Terns Pharmaceuticals for $53 a share, valuing the company at about $6.7 billion.
- Terns is developing a blood cancer therapy that showed positive results where prior treatments struggled, and the deal should close by July.
Arm Will Make And Sell AGI CPU Chips
- Arm plans to sell its own chips called AGI CPU and expects about $15 billion in annual revenue within five years.
- The move targets data centers, with Meta as the first major customer and contrasts with last year's $4 billion total sales.
Braze Beats Revenue Outlook Fueled By Early AI Products
- Braze forecasted first quarter revenue above $200 million, beating street expectations and lifting shares over 20% in pre-market trading.
- The company cited early AI product launches and 50% year-over-year fourth-quarter bookings growth despite adjusted earnings missing targets.